



DATE: July 19, 2018

TO: ACTG and IMPAACT (U.S.) Laboratories

FROM: Dr. Grace Aldrovandi, ACTG Network and IMPAACT Network Laboratory Principal Investigator
ACTG Laboratory Science Group
IMPAACT Laboratory Center

Subject: New Vendor for IMPAACT/ACTG Network-approved FBS: Nucleus Biologics

We are pleased to inform you that IMPAACT and ACTG Networks are now working with Nucleus Biologics to offer an additional, network-approved option for heat-inactivated Fetal Bovine Serum (Australian Origin FBS Ref# 1824-003) for use in PBMC cryopreservation.

As with all available lots of FBS approved for network use, the new product has undergone a successful lot-to-lot comparison for PBMC viability and recovery following cryopreservation through the Duke Human Vaccine Institute Immunology Quality Assurance (IQA) Program.

We have negotiated with Nucleus Biologics a price of \$389 per 500mL bottle, available through March 2020. Additionally, each member laboratory can take advantage of waived shipping and handling fees on one shipment per calendar year with a minimum order of nine (9) bottles.

FBS ordering details and product information for network approved lots, including the Certificate of Analysis (CoA), are available on the HANC webpage:

<https://www.hanc.info/labs/labresources/procedures/Pages/ActgImpaactFbsOrdering.aspx>

As Nucleus Biologics is a new vendor for the IMPAACT/ACTG networks, we would like to offer you an opportunity to be in touch with our contact, Steve Orzell, to introduce you to the company and answer any questions you may have on their products or placing orders.

Steve Orzell, Director
Nucleus Biologics
Phone: (617) 291-9449
Email: sorzell@nucleusbiologics.com

Other questions can be directed to:
IMPAACT Laboratory Center (impaact.gaqc@fstrf.org)
ACTG Laboratory Center (actglaboratorycoordination@s-3.com)